Equities research analysts expect that Aduro BioTech Inc (NASDAQ:ADRO) will post sales of $4.73 million for the current quarter, according to Zacks. Four analysts have provided estimates for Aduro BioTech’s earnings. The highest sales estimate is $5.80 million and the lowest is $3.50 million. Aduro BioTech posted sales of $2.76 million during the same quarter last year, which suggests a positive year over year growth rate of 71.4%. The company is scheduled to report its next quarterly earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Aduro BioTech will report full-year sales of $17.98 million for the current year, with estimates ranging from $15.83 million to $19.40 million. For the next year, analysts anticipate that the firm will report sales of $18.93 million, with estimates ranging from $14.00 million to $25.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.03. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.55 million. Aduro BioTech had a negative return on equity of 78.64% and a negative net margin of 544.94%.
Aduro BioTech stock opened at $1.10 on Friday. Aduro BioTech has a fifty-two week low of $0.90 and a fifty-two week high of $4.59. The stock’s 50 day simple moving average is $1.04 and its two-hundred day simple moving average is $1.72. The company has a debt-to-equity ratio of 0.39, a quick ratio of 7.26 and a current ratio of 7.26. The stock has a market cap of $87.76 million, a price-to-earnings ratio of -0.95 and a beta of 1.48.
In related news, CEO Stephen T. Isaacs sold 31,098 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $1.31, for a total value of $40,738.38. Following the completion of the transaction, the chief executive officer now owns 295,926 shares of the company’s stock, valued at approximately $387,663.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 52,185 shares of company stock valued at $68,362 in the last ninety days. 5.20% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of ADRO. Baillie Gifford & Co. lifted its stake in Aduro BioTech by 6.2% in the 2nd quarter. Baillie Gifford & Co. now owns 4,070,724 shares of the biotechnology company’s stock worth $6,269,000 after purchasing an additional 239,298 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Aduro BioTech by 63.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,400 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 22,700 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Aduro BioTech by 196.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,414,065 shares of the biotechnology company’s stock worth $2,474,000 after purchasing an additional 937,166 shares in the last quarter. Northern Trust Corp lifted its stake in Aduro BioTech by 1.6% in the 2nd quarter. Northern Trust Corp now owns 759,916 shares of the biotechnology company’s stock worth $1,171,000 after purchasing an additional 12,133 shares in the last quarter. Finally, Alambic Investment Management L.P. purchased a new stake in Aduro BioTech in the 2nd quarter worth $62,000. 41.55% of the stock is owned by institutional investors.
Aduro BioTech Company Profile
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
See Also: What is the Quick Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.